These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15665626)

  • 41. Continuous infusion interleukin-2 and antihistamines in melanoma: a retrospective review showing activity of this combination.
    Evangelista-Dean M; Khan N; Quan W
    Cancer Biother Radiopharm; 2004 Dec; 19(6):754-7. PubMed ID: 15665623
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of malignant melanoma with interleukin-2.
    Philip PA; Flaherty L
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S32-8. PubMed ID: 9122732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
    Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: a phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group).
    Dillman RO; Wiemann MC; VanderMolen LA; Bury MJ; DePriest C; Church C
    Cancer Biother Radiopharm; 1997 Aug; 12(4):249-55. PubMed ID: 10851472
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intra-lesional interleukin-2 for the treatment of in-transit melanoma.
    Boyd KU; Wehrli BM; Temple CL
    J Surg Oncol; 2011 Dec; 104(7):711-7. PubMed ID: 21744347
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
    Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
    Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
    Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
    Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
    Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
    Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
    Guillot B; Portalès P; Thanh AD; Merlet S; Dereure O; Clot J; Corbeau P
    Br J Dermatol; 2005 Apr; 152(4):690-6. PubMed ID: 15840100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
    Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-2 for the treatment of melanoma.
    Tarhini AA; Agarwala SS
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1234-9. PubMed ID: 16370388
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.
    Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH; Sznol M; Mier J; Sparano J; Fisher RI; Weiss G
    J Clin Oncol; 1991 Apr; 9(4):641-8. PubMed ID: 2066760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].
    Mitchell MS; Kempf RA; Harel W; Shau H; Boswell WD; Lind S; Bradley EC
    J Clin Oncol; 1988 Mar; 6(3):409-24. PubMed ID: 2965219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects.
    Samlowski WE; Petersen R; Cuzzocrea S; Macarthur H; Burton D; McGregor JR; Salvemini D
    Nat Med; 2003 Jun; 9(6):750-5. PubMed ID: 12730689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.
    Slavik M; Liu PY; Kraut EH; Natale RB; Flaherty LE; Sondak VK
    Invest New Drugs; 1995; 13(2):143-7. PubMed ID: 8617577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
    King DM; Albertini MR; Schalch H; Hank JA; Gan J; Surfus J; Mahvi D; Schiller JH; Warner T; Kim K; Eickhoff J; Kendra K; Reisfeld R; Gillies SD; Sondel P
    J Clin Oncol; 2004 Nov; 22(22):4463-73. PubMed ID: 15483010
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer.
    Paciucci PA; Holland JF; Glidewell O; Odchimar R
    J Clin Oncol; 1989 Jul; 7(7):869-78. PubMed ID: 2661733
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin.
    Sosman JA; Kohler PC; Hank JA; Moore KH; Bechhofer R; Storer B; Sondel PM
    J Natl Cancer Inst; 1988 Nov; 80(18):1451-61. PubMed ID: 3263508
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma.
    Coates A; Rallings M; Hersey P; Swanson C
    J Interferon Res; 1986 Feb; 6(1):1-4. PubMed ID: 2871116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.